Alerts will be sent to your verified email
Verify Email
ERIS
|
Eris Lifesciences
|
Pfizer
|
Wockhardt
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Domestic Sales Growth - YoY
|
6.1 % | 4.8 % | 10.6 % |
|
R&D as a % of Total Sales
|
0.0 | n/a | 4.6 % |
|
Financials
|
|||
|
5 yr Average ROE
|
17.74 % | 19.03 % | -3.51 % |
|
5yr average Equity Multiplier
|
1.76 | 1.25 | 2.02 |
|
5yr Average Asset Turnover Ratio
|
0.51 | 0.6 | 0.39 |
|
5yr Avg Net Profit Margin
|
22.76 % | 26.04 % | -4.28 % |
|
Price to Book
|
8.61 | 5.48 | 6.01 |
|
P/E
|
69.85 | 30.1 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
-54.68 Days | 21.86 Days | -94.15 Days |
|
Inventory Days
|
27.48 Days | 49.93 Days | 61.29 Days |
|
Days Receivable
|
54.07 Days | 29.1 Days | 60.36 Days |
|
Days Payable
|
148.48 Days | 77.28 Days | 251.45 Days |
|
5yr Average Interest Coverage Ratio
|
66.44 | 185.18 | -0.43 |
|
5yr Avg ROCE
|
18.34 % | 23.84 % | -0.28 % |
|
5yr Avg Operating Profit Margin
|
34.43 % | 31.72 % | 5.03 % |
|
5 yr average Debt to Equity
|
0.46 | 0.0 | 0.56 |
|
5yr CAGR Net Profit
|
-0.19 % | 76.68 % | n/a |
|
5yr Average Return on Assets
|
12.4 % | 15.25 % | -1.79 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
54.83 % | 63.92 % | 49.09 % |
|
Share Pledged by Promoters
|
16.93 % | 0.0 | 15.64 % |
|
Change in Promoter Holding (3 Yrs)
|
2.53 % | 0.0 | -16.66 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
6.42 % | 4.53 % | 7.99 % |
|
Eris Lifesciences
|
Pfizer
|
Wockhardt
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Entity Wise Breakup
|
Entity Wise Breakup
|
-
|
-
|
|
EBITDA - Entity Wise
|
EBITDA - Entity Wise
|
-
|
-
|
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
-
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Acute vs Chronic
|
Acute vs Chronic
|
-
|
-
|